TY - JOUR
T1 - Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers
AU - Wang, Yumeng
AU - Xu, Xiaoyan
AU - Yu, Shuangxing
AU - Jeong, Kang Jin
AU - Zhou, Zhicheng
AU - Han, Leng
AU - Tsang, Yiu Huen
AU - Li, Jun
AU - Chen, Hu
AU - Mangala, Lingegowda S.
AU - Yuan, Yuan
AU - Eterovic, A. Karina
AU - Lu, Yiling
AU - Sood, Anil K.
AU - Scott, Kenneth L.
AU - Mills, Gordon B.
AU - Liang, Han
N1 - Funding Information:
We acknowledge contributions from the TCGA Research Network and TCGA Pan-Cancer Analysis Working Group. This study was supported by the National Institutes of Health, National Cancer Institute (CA168394, CA098258, and U24CA143883 to G.B.M.; R01CA175486 and U24CA209851 to H.L.; and CCSG grant CA016672); the R. Lee Clark Fellow Award from The Jeanne F. Shelby Scholarship Fund; a grant from the Cancer Prevention and Research Institute of Texas (RP140462 to H.L.); and the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (to H.L.). We thank the MD Anderson high-performance computing core facility for computing and LeeAnn Chastain for editorial assistance.
Publisher Copyright:
© 2017 Wang et al.
PY - 2017/7
Y1 - 2017/7
N2 - RNA editing, a widespread post-transcriptional mechanism, has emerged as a new player in cancer biology. Recent studies have reported key roles for individual miRNA editing events, but a comprehensive picture of miRNA editing in human cancers remains largely unexplored. Here, we systematically characterized the miRNA editing profiles of 8595 samples across 20 cancer types from miRNA sequencing data of The Cancer Genome Atlas and identified 19 adenosine-to-inosine (A-to-I) RNA editing hotspots. We independently validated 15 of them by perturbation experiments in several cancer cell lines. These miRNA editing events show extensive correlations with key clinical variables (e.g., tumor subtype, disease stage, and patient survival time) and other molecular drivers. Focusing on the RNA editing hotspot in miR-200b, a key tumor metastasis suppressor, we found that the miR-200b editing level correlates with patient prognosis opposite to the pattern observed for the wild-type miR-200b expression. We further experimentally showed that, in contrast to wild-type miRNA, the edited miR-200b can promote cell invasion and migration through its impaired ability to inhibit ZEB1/ZEB2 and acquired concomitant ability to repress new targets, including LIFR, a well-characterized metastasis suppressor. Our study highlights the importance of miRNA editing in gene regulation and suggests its potential as a biomarker for cancer prognosis and therapy.
AB - RNA editing, a widespread post-transcriptional mechanism, has emerged as a new player in cancer biology. Recent studies have reported key roles for individual miRNA editing events, but a comprehensive picture of miRNA editing in human cancers remains largely unexplored. Here, we systematically characterized the miRNA editing profiles of 8595 samples across 20 cancer types from miRNA sequencing data of The Cancer Genome Atlas and identified 19 adenosine-to-inosine (A-to-I) RNA editing hotspots. We independently validated 15 of them by perturbation experiments in several cancer cell lines. These miRNA editing events show extensive correlations with key clinical variables (e.g., tumor subtype, disease stage, and patient survival time) and other molecular drivers. Focusing on the RNA editing hotspot in miR-200b, a key tumor metastasis suppressor, we found that the miR-200b editing level correlates with patient prognosis opposite to the pattern observed for the wild-type miR-200b expression. We further experimentally showed that, in contrast to wild-type miRNA, the edited miR-200b can promote cell invasion and migration through its impaired ability to inhibit ZEB1/ZEB2 and acquired concomitant ability to repress new targets, including LIFR, a well-characterized metastasis suppressor. Our study highlights the importance of miRNA editing in gene regulation and suggests its potential as a biomarker for cancer prognosis and therapy.
UR - http://www.scopus.com/inward/record.url?scp=85023769542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023769542&partnerID=8YFLogxK
U2 - 10.1101/gr.219741.116
DO - 10.1101/gr.219741.116
M3 - Article
C2 - 28411194
AN - SCOPUS:85023769542
SN - 1088-9051
VL - 27
SP - 1112
EP - 1125
JO - PCR Methods and Applications
JF - PCR Methods and Applications
IS - 7
ER -